Cytokinetics (CYTK) PT Raised to $63 at Raymond James
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts CYTK Hot Sheet
Price: $63.60 --0%
Rating Summary:
24 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 16 | New: 2
Rating Summary:
24 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 16 | New: 2
Join SI Premium – FREE
Raymond James analyst Dane Leone raised the price target on Cytokinetics (NASDAQ: CYTK) to $63.00 (from $54.00) while maintaining a Outperform rating.
You May Also Be Interested In
- Cytokinetics (CYTK) PT Raised to $105 at Citi
- Cytokinetics Announces Three Upcoming Presentations at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions Held in Collaboration with the American Heart Association Scientific S
- ADMA Biologics (ADMA) PT Raised to $18 at Mizuho
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
